BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 448074)

  • 1. Action of the C3b-inactivator on the cell-bound C3b.
    Law SK; Fearon DT; Levine RP
    J Immunol; 1979 Mar; 122(3):759-65. PubMed ID: 448074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement receptor binding of C3b-coated cells treated with C3b inactivator, beta 1H globulin and trypsin.
    Carlo JR; Ruddy S; Studer EJ; Conrad DH
    J Immunol; 1979 Aug; 123(2):523-8. PubMed ID: 88474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qualitative and quantitative assessment of C3-receptor reactivities on lymphoid and phagocytic cells.
    Schmitt M; Mussel HH; Dierich MP
    J Immunol; 1981 May; 126(5):2042-7. PubMed ID: 7217681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
    Medicus RG; Melamed J; Arnaout MA
    Eur J Immunol; 1983 Jun; 13(6):465-70. PubMed ID: 6222909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    J Exp Med; 1977 Jul; 146(1):257-70. PubMed ID: 301546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cleavage of C4b by C3b inactivator: production of a nicked form of C4b, C4b', as an intermediate cleavage product of C4b by C3b inactivator.
    Nagasawa S; Ichihara C; Stroud RM
    J Immunol; 1980 Aug; 125(2):578-82. PubMed ID: 7391570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effect of K-76 monocarboxylic acid, an anticomplementary agent, on the C3b inactivator system.
    Hong K; Kinoshita T; Kitajima H; Inoue K
    J Immunol; 1981 Jul; 127(1):104-8. PubMed ID: 7240739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
    Davis AE; Harrison RA; Lachmann PJ
    J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus.
    Whaley K; Schur PH; Ruddy S
    Clin Exp Immunol; 1979 Jun; 36(3):408-14. PubMed ID: 114347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse C3b/C4b inactivator: purification and properties.
    Kai S; Fujita T; Gigli I; Nussenzweig V
    J Immunol; 1980 Dec; 125(6):2409-15. PubMed ID: 6776193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third component of complement (C3): structural properties in relation to functions.
    Bokisch VA; Dierich MP; Mūller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1975 Jun; 72(6):1989-93. PubMed ID: 1056006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
    Whaley K; Schur PH; Ruddy S
    J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purification of the human complement control protein C3b inactivator.
    Crossley LG; Porter RR
    Biochem J; 1980 Oct; 191(1):173-82. PubMed ID: 6451220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstration of the complement regulating protein, beta 1H, in skin biopsies from patients with bullous pemphigoid.
    Carlo JR; Gammon WR; Sams WM; Ruddy S
    J Invest Dermatol; 1979 Dec; 73(6):551-3. PubMed ID: 390060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c.
    Laursen SB; Thiel S; Teisner B; Holmskov U; Wang Y; Sim RB; Jensenius JC
    Immunology; 1994 Apr; 81(4):648-54. PubMed ID: 7518801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes.
    Medof ME; Iida K; Mold C; Nussenzweig V
    J Exp Med; 1982 Dec; 156(6):1739-54. PubMed ID: 7175439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
    Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
    J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor-binding sites on C3 and C3b.
    Dierich MP; Bokisch VA
    J Immunol; 1977 Jun; 118(6):2145-50. PubMed ID: 864256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A molecular basis of activation of the alternative pathway of human complement.
    Austen KF; Fearon DT
    Adv Exp Med Biol; 1979; 120B():3-17. PubMed ID: 390986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.